Article
Biochemistry & Molecular Biology
Vivien Li, Michele D. Binder, Trevor J. Kilpatrick
Summary: Dendritic cells can induce anti-inflammatory/tolerogenic properties and promote immune tolerance. Dexamethasone can generate tolerogenic dendritic cells and upregulate MERTK expression. The study suggests that dexamethasone's tolerogenic effects are mediated via MERTK and may be exerted by increasing Rab17 expression to prevent the presentation of efferocytosed material on the cell surface.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Immunology
Charlotte Castenmiller, Brigitte-Carole Keumatio-Doungtsop, Ronald van Ree, Esther C. de Jong, Yvette van Kooyk
Summary: Dendritic cells play key roles in regulating immune responses by inducing either inflammatory or tolerogenic reactions. Research interest is growing in defining tolerance-inducing receptors on DCs for developing new immunotherapeutic strategies. Targeting strategies such as antigen-carbohydrate conjugates and antibody-antigen fusion proteins aim to induce a tolerogenic DC phenotype.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Mats Van Delen, Ibo Janssens, Amber Dams, Laurence Roosens, Benson Ogunjimi, Zwi N. Berneman, Judith Derdelinckx, Nathalie Cools
Summary: This study aimed to counter the high inflammatory state of COVID-19 by inducing T-cell hyporesponsiveness using tolerogenic dendritic cells (tolDC). The results showed that tolDC could induce SARS-CoV-2-specific T cell hyporesponsiveness, suggesting its clinical potential.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Marija Drakul, Sergej Tomic, Marina Bekic, Dusan Mihajlovic, Milos Vasiljevic, Sara Rakocevic, Jelena Dokic, Nikola Popovic, Dejan Bokonjic, Miodrag Colic
Summary: Sitagliptin has an effect on the differentiation and maturation of human dendritic cells, with decreased expression of some immune activity molecules and increased expression of some tolerogenic molecules. Sitagliptin-treated cells have lower ability to stimulate T-cells and suppress certain T-cell responses while enhancing immunoregulatory responses. This effect may be achieved through the inhibition of NF-kB and p38MAPK expression.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Immunology
Octavio Morante-Palacios, Federico Fondelli, Esteban Ballestar, Eva M. Martinez-Caceres
Summary: Dendritic cells play a crucial role in activating T cells and can acquire tolerogenic functions through various stimuli. Research shows that tolerogenic dendritic cells have potential clinical applications in treating inflammatory diseases.
TRENDS IN IMMUNOLOGY
(2021)
Article
Urology & Nephrology
Jennifer S. Y. Li, Harry Robertson, Katie Trinh, Arti M. Raghubar, Quan Nguyen, Nicholas Matigian, Ellis Patrick, Angus W. Thomson, Andrew J. Mallett, Natasha M. Rogers
Summary: Ischemia reperfusion injury is a common cause of acute kidney injury. Adoptively transferred tolerogenic dendritic cells can successfully limit kidney injury and provide protection against ischemia reperfusion injury.
KIDNEY INTERNATIONAL
(2023)
Review
Immunology
Nick Giannoukakis
Summary: Tolerogenic dendritic cells (tDC) have the potential to prevent the progression of autoimmune-driven dysglycemia into insulin-requiring type 1 diabetes (T1D) and preserve β cells. tDC act via multiple layers of immune regulation to suppress effector lymphocytes targeting β cells. It is now appropriate to conduct phase II clinical trials for T1D using well-characterized tDC.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Mohammed Ghiboub, Matthew Bell, Dovile Sinkeviciute, Rab K. Prinjha, Menno P. J. de Winther, Nicola R. Harker, David F. Tough, Wouter J. de Jonge
Summary: SP140 is a reader protein expressed in immune cells and is associated with autoimmune and inflammatory diseases. Inhibition of SP140 with GSK761 reduces the expression of inflammatory cytokines in macrophages and impairs the maturation of dendritic cells. The study suggests that targeting SP140 may be beneficial in autoimmune and inflammatory diseases.
CURRENT ISSUES IN MOLECULAR BIOLOGY
(2023)
Review
Immunology
Jessica Bourque, Daniel Hawiger
Summary: In contrast to cDCs constantly exposed to microbial signals, cDCs in systemic lymphoid organs are protected in the steady state but gain immune functions upon inflammatory signals, referred to as maturation. Recent findings show that a population of tolerogenic cDCs undergo cell death mediated by TNF alpha during maturation, resulting in loss of tolerance. These tolerogenic cDCs can be restored upon return to baseline, providing a framework for maintaining tolerance and initiating immune responses under inflammatory conditions.
TRENDS IN IMMUNOLOGY
(2023)
Article
Multidisciplinary Sciences
Hee Su Sohn, Jeong Won Choi, JooYeon Jhun, Sung Pil Kwon, Mungyo Jung, Sangmin Yong, Hyun Sik Na, Jin-Hong Kim, Mi-La Cho, Byung-Soo Kim
Summary: This study describes an immunomodulating nanoparticle for the treatment of osteoarthritis. Injecting these nanoparticles into the joints of mice effectively suppressed inflammation, reduced inflammatory cells and cytokines, and improved the condition of chondrocytes, leading to pain relief.
Article
Immunology
Alba Angelina, Mario Perez-Diego, Jacobo Lopez-Abente, Beate Ruckert, Ivan Nombela, Mubeccel Akdis, Mar Martin-Fontecha, Cezmi Akdis, Oscar Palomares
Summary: Cannabinoids have been found to promote tolerogenic dendritic cells and generate functional FOXP3(+) Tregs, demonstrating immunomodulatory effects in different inflammatory diseases. The mechanism involves metabolic rewiring towards increased mitochondrial activity and oxidative phosphorylation through the activation of CB1 and PPAR alpha.
MUCOSAL IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Tamara Saksida, Bojan Jevtic, Neda Djedovic, Dorde Miljkovic, Ivana Stojanovic
Summary: Autoimmune diseases are on the rise in western societies, with increasing focus on the role of reactive oxygen species (ROS) in immune response modulation. Recent studies highlight the importance of ROS in the function of dendritic cells (DC) and T cells. However, the effectiveness of ROS modulation in directing T cells and DCs towards a tolerogenic phenotype remains unclear. The potential use of ROS modulation to enhance the regulatory properties of DC and Treg in cell-based immunotherapy also requires further clarification for future therapeutic applications.
ANTIOXIDANTS & REDOX SIGNALING
(2021)
Article
Immunology
Astrid L. L. Voskamp, Tamar Tak, Maarten L. L. Gerdes, Roberta Menafra, Ellen Duijster, Szymon M. M. Kielbasa, Tom Groot Kormelink, Koen A. A. Stam, Oscar R. J. van Hengel, Nicolette W. W. de Jong, Rudi W. W. Hendriks, Susan L. L. Kloet, Maria Yazdanbakhsh, Esther C. C. de Jong, Roy Gerth van Wijk, Hermelijn H. H. Smits
Summary: This study investigated the role of innate mononuclear phagocytic system (MPS) cells in preserving mucosal immune homeostasis and their response to allergen challenge. It was found that allergic rhinitis patients exhibited an inflammatory response while non-allergic individuals displayed a tolerizing/anti-inflammatory response to allergen challenge. These findings suggest that future therapies should consider targeting the activity of myeloid-derived suppressor cells (MDSC) as a treatment for inflammatory airway diseases.
JOURNAL OF EXPERIMENTAL MEDICINE
(2023)
Article
Chemistry, Multidisciplinary
Sujing Sun, Chulin He, Chenyan Li, Dongxin Peng, Wenyuan Bai, Yulong Zhang, MinWei He, Liping Lv, Yanrong Dong, Ping Ma, Qianqian Zhou, Linsheng Zhan, Xiaohui Wang
Summary: This study presents a novel approach for generating tolerogenic dendritic cells (TDCs) using a graphene oxide (GO) nanosheet-based platform for neuropeptide delivery. The results demonstrate that the generated TDCs exhibit enhanced migration ability and immunoregulatory function in vivo, leading to significant relief of graft-versus-host disease (GVHD).
Article
Immunology
Cecilia Svanberg, Sofia Nystrom, Melissa Govender, Pradyot Bhattacharya, Karlhans F. Che, Rada Ellegard, Esaki M. Shankar, Marie Larsson
Summary: HIV-1 infection leads to immune impairment in infected individuals. DCs in contact with HIV-1 exhibit a tolerogenic phenotype and show characteristics of suppressive T cells in the transcriptome, possibly due to prolonged and strong type I IFN signaling in DCs.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Medicine, Research & Experimental
Damian Garcia-Olmo, Gert Van Assche, Ignacio Tagarro, Mary Carmen Diez, Marie Paule Richard, Javaria Mona Khalid, Marc van Dijk, Dimitri Bennett, Suvi R. K. Hokkanen, Julian Panes
ADVANCES IN THERAPY
(2019)
Article
Gastroenterology & Hepatology
Bruce E. Sands, Alessandro Armuzzi, John K. Marshall, James O. Lindsay, William J. Sandborn, Silvio Danese, Julian Panes, Brian Bressler, Jean-Frederic Colombel, Nervin Lawendy, Eric Maller, Haiying Zhang, Gary Chan, Leonardo Salese, Konstantinos Tsilkos, Amy Marren, Chinyu Su
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2020)
Article
Gastroenterology & Hepatology
William J. Sandborn, Subrata Ghosh, Julian Panes, Stefan Schreiber, Geert D'Haens, Satoshi Tanida, Jesse Siffledeen, Jefferey Enejosa, Wen Zhou, Ahmed A. Othman, Bidan Huang, Peter D. R. Higgins
Article
Gastroenterology & Hepatology
Jordi Rimola, Agnes Fernandez-Clotet, Nunzia Capozzi, Sonia Rojas-Farreras, Ignacio Alfaro, Sonia Rodriguez, Maria-Carme Masamunt, Elena Ricart, Ingrid Ordas, Julian Panes
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2020)
Article
Gastroenterology & Hepatology
Severine Vermeire, Michael Chiorean, Julian Panes, Laurent Peyrin-Biroulet, Jinkun Zhang, Bruce E. Sands, Krisztina Lazin, Preston Klassen, Snehal U. Naik, Christopher H. Cabell, William J. Sandborn
Summary: The study showed that treatment with 2 mg Etrasimod has significant benefits and good safety for patients with ulcerative colitis. Most patients maintained their clinical response, clinical remission, or endoscopic improvement status at the end of treatment.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Gastroenterology & Hepatology
Julian Panes, Severine Vermeire, Marla C. Dubinsky, Edward V. Loftus, Nervin Lawendy, Wenjin Wang, Leonardo Salese, Chinyu Su, Irene Modesto, Xiang Guo, Jean-Frederic Colombel
Summary: In patients with ulcerative colitis, re-treatment with tofacitinib can effectively and safely recapture efficacy, regardless of prior treatment failure. Specific efficacy data show that a substantial proportion of patients can achieve clinical response and remission with tofacitinib re-treatment.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Gastroenterology & Hepatology
William J. Sandborn, James D. Lewis, Julian Panes, Edward Loftus, Geert D'Haens, Zhuqing Yu, Bidan Huang, Ana P. Lacerda, Aileen L. Pangan, Brian G. Feagan
Summary: This study examined the association between patient-reported general well-being and symptoms of diarrhea and abdominal pain in patients with moderate to severe Crohn's disease. The findings suggest that improvements in patient-reported general well-being are related to clinical remission/response, supporting the endpoint definitions used in clinical studies of Crohn's disease.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Gastroenterology & Hepatology
Marc Ferrante, Brian G. Feagan, Julian Panes, Filip Baert, Edouard Louis, Olivier Dewit, Arthur Kaser, W. Rachel Duan, Yinuo Pang, Wan-Ju Lee, Dawn Gustafson, Xiaomei Liao, Kori Wallace, Jasmina Kalabic, Geert R. D'Haens
Summary: The study demonstrated that long-term maintenance treatment with subcutaneous risankizumab 180 mg every 8 weeks was well tolerated by patients with moderate-to-severe refractory Crohn's disease, with no new safety signals observed. Efficacy outcomes were maintained, including high proportions of patients with clinical and endoscopic remission.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Gastroenterology & Hepatology
Subrata Ghosh, Yuri Sanchez Gonzalez, Wen Zhou, Ryan Clark, Wangang Xie, Edouard Louis, Edward Loftus, Julian Panes, Silvio Danese
Summary: In the study, treatment with upadacitinib significantly reduced bowel urgency and abdominal pain symptoms compared to placebo, with these symptoms correlating to clinical and HRQOL outcomes to a certain extent.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Gastroenterology & Hepatology
Julian Panes, Gerd Bouma, Marc Ferrante, Torsten Kucharzik, Maria Nachury, Fernando de la Portilla de Juan, Walter Reinisch, Francesco Selvaggi, Jorg Tschmelitsch, Neil R. Brett, Martin Ladouceur, Matthias Binek, Gary Hantsbarger, Sarah Campbell-Hill, Chitra Karki, Christianne Buskens
Summary: This retrospective chart review study confirms that darvadstrocel can provide sustained remission of complex perianal fistulas in patients with Crohn's disease, and it has a favorable long-term safety profile.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Medicine, General & Internal
Cristina Romero-Mascarell, Gloria Fernandez-Esparrach, Cristina Rodriguez-De Miguel, Maria Carme Masamunt, Sonia Rodriguez, Jordi Rimola, Miguel Urpi, Gherzon Simon Casanova, Ingrid Ordas, Elena Ricart, Berta Caballol, Agnes Fernandez-Clotet, Julia Panes, Josep Llach, Begona Gonzalez-Suarez
Summary: The study found a good correlation between fecal calprotectin (FC) levels and small bowel lesions in patients with established or suspected Crohn's disease. The ideal cutoff value for FC was found to be higher than previously reported, indicating the need for further research to establish definitive FC cutoff levels.
Article
Gastroenterology & Hepatology
Julian Panes, Edward Loftus, Peter D. R. Higgins, James O. Lindsay, Wen Zhou, Xuan Yao, Dapo Ilo, Charles Phillips, Jacinda Tran, Yuri Sanchez Gonzalez, Severine Vermeire
Summary: The study evaluated the benefits of UPA on the HRQoL of patients with ulcerative colitis, and found that UPA treatment significantly improved patients' quality of life.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Julian Panes, Severine R. Vermeire, Geert D'Haens, Silvio Danese, Fernando Magro, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana R. Bravata, Daniel Gaya, Laurent Peyrin-Biroulet, Axel Dignass
Summary: This study compared two treatment strategies for Crohn's disease patients and found that regardless of whether the treatment was "treat-to-target" or "standard of care", ustekinumab was effective in improving the health-related quality of life and work productivity of patients over a 2-year follow-up period.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2023)
Article
Gastroenterology & Hepatology
Laurent Peyrin-Biroulet, Severine Vermeire, Geert D'Haens, Julian Panes, Axel Dignass, Fernando Magro, Maciej Nazar, Manuela Le Bars, Marjolein Lahaye, Lioudmila Ni, Ivana Bravata, Frederic Lavie, Marco Daperno, Milan Lukas, Alessandro Armuzzi, Mark Loewenberg, Daniel R. Gaya, Silvio Danese
Summary: The STARDUST LTE study is the first interventional study to investigate the efficacy of ustekinumab in Crohn's disease. The study showed that flexible, algorithm-driven dose adjustment, including dose reduction, preserved clinical and endoscopic outcomes for up to 104 weeks.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Letter
Gastroenterology & Hepatology
Jordi Rimola, Julian Panes, Ingrid Ordas
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)